Human mitochondrial malate dehydrogenase

• US 6,274,138 B1
• Filed: 09/03/1997
• Issued: 08/14/2001
• Est. Priority Date: 09/03/1997
• Status: Expired due to Fees

• Current Assignee: Incyte Pharmaceuticals, Inc. (Incyte Corporation)
• Original Assignee: Incyte Genomics, Inc. (Incyte Corporation)
• Inventors: Corley, Neil C., Bandman, Olga, Shah, Purvi
• Primary Examiner(s): Nashed, Nashaat T.
• Assistant Examiner(s): Fronda, Christian L.
• Application Number:
  US08/922,957
• Time in Patent Office: 1,441 Days
• Field of Search: 435/189, 435/26, 424/94.4
• US Class Current: 424/94.4
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C12N 9/0006 acting on CH-OH groups as donors (1.1)
• CPC Class Codes: C12Y 101/01037 Malate dehydrogenase (1.1.1.37)

Abstract

The invention provides a human mitochondrial malate dehydrogenase (MT-MDH) and polynucleotides which identify and encode MT-MDH. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of MT-MDH.

Claims

1. An isolated polypeptide selected from the group consisting of:

a) a polypeptide comprising the amino acid sequence of SEQ ID NO;

1, and

b) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO;

1,

wherein said fragment has malate dehydrogenase activity.

2. The polypeptide of claim 1, having the amino acid sequence of SEQ ID NO:

1.

3. A composition comprising the polypeptide of claim 1 and an excipient.

4. A method of screening a compound for effectiveness as an activator of a polypeptide of claim 1, the method comprising:

a) exposing a sample comprising a polypeptide of claim 1 to a compound, and

b) detecting, directly or indirectly, an increase of malate dehydrogenase activity.

5. A method of screening a compound for effectiveness as an inhibitor of a polypeptide of claim 1, the method comprising:

a) exposing a sample comprising a polypeptide of claim 1 to a compound, and

b) detecting directly or indirectly, an decrease of malate dehydrogenase activity.